|

PD-1inhibitor Clinical Trials

3 actively recruiting trials

Also known as: Immunotherapy, PD-1 antibody

Pipeline

Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1
  • Shanghai Chest Hospital1
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences1

Indications

  • Cancer3
  • Unresectable Locally Advanced Esophageal Cancer1
  • HNSCC1
  • PD-11
  • Esophageal Squamous Cell Carcinoma1

Other3 trials

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
Phase 1/2
PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.